SLAMF7 and Miyoshi myopathy: The introduction of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) led to a dramatic improvement in clinical outcomes for MM, which were further enhanced by the development of monoclonal antibody therapies targeting CD38 and SLAMF7 [3,4].